🇺🇸 FDA
Pipeline program

Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

ARGX-113-2308

Phase 3 small_molecule active

Quick answer

Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion for Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials